शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
LYKALABSNSELyka Labs Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Fri, 5 Dec, 2025 · 16:00 IST

NCLT reserves order on Lyka Exports merger with Lyka Labs

Scheme filed with the NCLTStrategic Transactions View source PDFExplain this filing

LYKALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-4.4%Reaction day
₹77.32
prior close
₹77.43
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-2.4%-2.0% vs market
Pharmaceuticals peers, median of 156sector-2.0%-2.4% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.0
10m
-0.0
15m
-1.1
30m
-0.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-4.4-2.4-2.0-2.0-2.4
Next day
+0.2-0.4+0.7-1.4+1.6
2d
+3.4-1.1+4.5-1.4+4.9
3d
+0.9-0.6+1.5-1.0+1.9
4d
+0.2-0.4+0.5-0.8+1.0
5d
-0.4+0.1-0.5-0.6+0.2
1w
-3.3-1.4-1.9-2.1-1.1
15d
-1.8-1.0-0.8-2.1+0.3
1m
+2.2-0.8+2.9-1.4+3.6
2m
-8.8-0.9-7.9-5.0-3.8
3m
-26.5-11.3-15.3-10.8-15.7
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Lyka Labs informed NSE that the NCLT Ahmedabad has reserved its order on the Scheme of Amalgamation between Lyka Exports (transferor) and Lyka Labs (transferee). The Income Tax Department has no objection to the merger. This follows an earlier intimation dated 8 November 2025.

Likely market impact

NCLT has reserved order after Income Tax raised no objection, which is a positive step for merger approval. Awaiting final order.